Concepts (80)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Cosmetic Techniques | 3 | 2020 | 167 | 1.43 | Why? |
| Lip | 2 | 2019 | 61 | 0.96 | Why? |
| Lichenoid Eruptions | 1 | 2019 | 22 | 0.81 | Why? |
| Tattooing | 1 | 2019 | 27 | 0.80 | Why? |
| Hyperpigmentation | 1 | 2019 | 42 | 0.77 | Why? |
| Coloring Agents | 1 | 2019 | 116 | 0.74 | Why? |
| Granuloma, Foreign-Body | 1 | 2018 | 6 | 0.74 | Why? |
| Dimethylpolysiloxanes | 1 | 2018 | 46 | 0.73 | Why? |
| Dermal Fillers | 1 | 2018 | 41 | 0.69 | Why? |
| Edema | 1 | 2018 | 333 | 0.55 | Why? |
| Facial Dermatoses | 1 | 2018 | 222 | 0.54 | Why? |
| Erythema | 1 | 2018 | 400 | 0.51 | Why? |
| Cost of Illness | 1 | 2020 | 1903 | 0.38 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.28 | Why? |
| Elective Surgical Procedures | 1 | 2020 | 5338 | 0.23 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.22 | Why? |
| Hydroxychloroquine | 4 | 2021 | 12447 | 0.22 | Why? |
| Pigmentation | 1 | 2019 | 21 | 0.21 | Why? |
| Sitagliptin Phosphate | 1 | 2020 | 82 | 0.20 | Why? |
| Esthetics | 1 | 2020 | 136 | 0.20 | Why? |
| Foreign-Body Migration | 1 | 2018 | 25 | 0.18 | Why? |
| Gels | 1 | 2018 | 111 | 0.17 | Why? |
| Interferon beta-1a | 1 | 2020 | 316 | 0.17 | Why? |
| Hemoperfusion | 1 | 2020 | 260 | 0.16 | Why? |
| Global Burden of Disease | 1 | 2020 | 531 | 0.16 | Why? |
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2020 | 436 | 0.14 | Why? |
| Immunologic Factors | 2 | 2020 | 4206 | 0.13 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1316 | 0.12 | Why? |
| Nigeria | 1 | 2019 | 2292 | 0.12 | Why? |
| Renal Replacement Therapy | 1 | 2020 | 1530 | 0.11 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 9335 | 0.10 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.10 | Why? |
| Dexamethasone | 1 | 2021 | 2055 | 0.10 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.10 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.10 | Why? |
| Immunoglobulins, Intravenous | 1 | 2020 | 2705 | 0.09 | Why? |
| Injections, Subcutaneous | 2 | 2020 | 647 | 0.09 | Why? |
| Infusions, Intravenous | 2 | 2020 | 1224 | 0.08 | Why? |
| Interleukin-6 | 2 | 2020 | 7522 | 0.07 | Why? |
| Treatment Failure | 2 | 2021 | 2106 | 0.07 | Why? |
| Anti-Inflammatory Agents | 1 | 2021 | 6153 | 0.06 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 5002 | 0.06 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.06 | Why? |
| Pandemics | 8 | 2020 | 389249 | 0.05 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.05 | Why? |
| Adult | 7 | 2021 | 244371 | 0.04 | Why? |
| Humans | 14 | 2021 | 930598 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.04 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.04 | Why? |
| Lopinavir | 2 | 2020 | 4308 | 0.04 | Why? |
| Ritonavir | 2 | 2020 | 4212 | 0.04 | Why? |
| Lung | 5 | 2020 | 31049 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2020 | 1444 | 0.03 | Why? |
| Female | 6 | 2021 | 380317 | 0.03 | Why? |
| Treatment Outcome | 4 | 2021 | 51732 | 0.03 | Why? |
| Dipeptidyl Peptidase 4 | 1 | 2020 | 1061 | 0.03 | Why? |
| Length of Stay | 2 | 2021 | 11042 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.02 | Why? |
| Tomography, X-Ray Computed | 3 | 2021 | 25144 | 0.02 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.02 | Why? |
| Middle Aged | 6 | 2021 | 270681 | 0.02 | Why? |
| Iran | 1 | 2020 | 5467 | 0.02 | Why? |
| Male | 6 | 2021 | 367725 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Prospective Studies | 2 | 2020 | 43301 | 0.02 | Why? |
| Aged | 4 | 2021 | 215776 | 0.02 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.02 | Why? |
| Antibodies, Monoclonal | 1 | 2020 | 8041 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.01 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.01 | Why? |
| Young Adult | 1 | 2020 | 93724 | 0.01 | Why? |
| Retrospective Studies | 1 | 2020 | 105322 | 0.01 | Why? |
Saffaei's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(80)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(68)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_